cilostazol has been researched along with Injury, Myocardial Reperfusion in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J | 3 |
| Xiang, X | 3 |
| Xu, H | 1 |
| Shi, Y | 2 |
| Gülaştı, ÖF | 1 |
| Yavuz, Ş | 1 |
| Arıkan, AA | 1 |
| Eraldemir, FC | 1 |
| Özbudak, E | 1 |
| Şahin, D | 1 |
| Kır, HM | 1 |
| Gong, X | 1 |
| Yang, J | 1 |
| Xu, Z | 2 |
| Ye, Y | 1 |
| Perez-Polo, JR | 1 |
| Birnbaum, Y | 1 |
1 review available for cilostazol and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their potential interactions.
Topics: Aspirin; Cilostazol; Dipyridamole; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase In | 2010 |
4 other studies available for cilostazol and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Cilostazol Promotes Angiogenesis and Increases Cell Proliferation After Myocardial Ischemia-Reperfusion Injury Through a cAMP-Dependent Mechanism.
Topics: Angiogenesis Inducing Agents; Animals; Apoptosis; Cell Hypoxia; Cell Proliferation; Cells, Cultured; | 2019 |
Comparison of Cilostazol and Naftidrofuryl in an Experimental Acute Ischemia-Reperfusion Model.
Topics: Animals; Antioxidants; Biomarkers; Brain; Cilostazol; Disease Models, Animal; Kidney; Liver; Male; M | 2021 |
Cilostazol protects mice against myocardium ischemic/reperfusion injury by activating a PPARγ/JAK2/STAT3 pathway.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Cardiotonic Agents; Caspase 3; Cilostazol; Interl | 2017 |
Cilostazol protects against myocardial ischemia and reperfusion injury by activating transcription factor EB (TFEB).
Topics: Animals; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cilostazol; Disease | 2019 |